

Breast Ca Survival Tied to Hormone Therapy

BY BRUCE JANCIN
Denver Bureau

SAN ANTONIO — Breast cancer patients who used menopausal hormone therapy before their diagnosis had a reduced breast cancer mortality, compared with never-users of hormone therapy, in the large epidemiologic California Teachers Study.

Users of estrogen plus progestin hormone therapy who developed breast cancer had an unadjusted 63% relative risk reduction in breast cancer-specific mortality, compared with HT never-users with the malignancy. The fully adjusted

“Use of these hormones appears to be a benefit in terms of protecting against risk of cancer death,” she observed. “This may allow women who have used hormones and who are worried about future breast cancer risk—or even their prognosis if they currently have cancer—to breathe a little easier.”

But Dr. Susan Love, who wasn't involved in the study, had a different take on the results.

“HT causes more cancers; it's just that they're, quote, 'good' cancers. But those 'good' cancers still need surgery, radiation, aromatase inhibitors, maybe chemotherapy. So I think, as a woman, there is no such thing as a 'good' cancer if it's in you. You don't know it's a good cancer until you die at 95 of a stroke,” observed Dr. Love of the University of California, Los Angeles, and president of the Dr. Susan Love Research Foundation.

Moreover, it's controversial whether breast cancer in women who have used HT is associated with improved survival. It was reported elsewhere at the San Antonio meeting that 5-year mortality in roughly 2,000 breast cancer patients in the Women's Health Initiative Observational Study was virtually identical, regardless of whether they had used estrogen-progestin HT or were HT never-users. ■



'Use of these hormones appears to be a benefit in terms of protecting against risk of cancer death.'

MS. MARSHALL

reduction in the risk of breast cancer mortality in patients with a history of estrogen-progestin HT was 47%, compared with HT never-users, Sarah F. Marshall reported at the San Antonio Breast Cancer Symposium.

In breast cancer patients with a history of estrogen-only HT use, the unadjusted relative risk reduction in mortality due to breast cancer was 36%, compared with HT never-users. However, upon fully adjusting for race, lymph node status, comorbidities, type of treatment, smoking, body mass index, and physical activity, as well as tumor stage, size, grade, and estrogen-receptor status, the relative risk reduction shrank to 18%, which was no longer statistically significant, according to Ms. Marshall of the University of California, Irvine.

The California Teachers Study is an ongoing epidemiologic study involving 133,479 female teachers and administrators. Ms. Marshall reported on 2,783 postmenopausal participants diagnosed with breast cancer during 1995-2005. Their mean age at diagnosis was 68 years.


During a mean 5 years of follow-up, 13% of the breast cancer patients died of any cause, and 5.7% died of breast cancer. The breast cancer mortality rate was 9% in HT never-users, 6% in women who had used estrogen-only HT, and 4% in those who took estrogen-progestin. Statistical adjustment for potential confounders was necessary because HT users were as a group leaner, got more exercise, had fewer comorbidities, and their tumors were smaller, lower grade, and less aggressive.

This was the first study ever to adjust for a full range of tumor characteristics, including estrogen-receptor status, Ms. Marshall said.

HT is known to increase breast cancer risk. Ms. Marshall speculated that HT may sensitize the tumors to hormones, making them more responsive to treatment involving hormonal deprivation.

Relax, we've got painful muscle spasm under control.

amrix[®]
Cyclobenzaprine HCl
Extended-Release Capsules



Once-daily AMRIX...the proven efficacy of cyclobenzaprine with low rates of somnolence.¹

AMRIX (Cyclobenzaprine Hydrochloride Extended-Release Capsules) is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. AMRIX should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. AMRIX has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy.

AMRIX is contraindicated in patients who are hypersensitive to any of its components. AMRIX is contraindicated with concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. AMRIX may have life-threatening interactions with MAO inhibitors. AMRIX is contraindicated during the acute recovery phase of myocardial infarction; in patients with arrhythmias, heart block conduction disturbances, or congestive heart failure; or in patients with hyperthyroidism. AMRIX may enhance the effects of alcohol, barbiturates, and other CNS depressants. AMRIX should not be used in elderly patients or in patients with impaired hepatic function.

In clinical trials, the most commonly reported adverse reactions ($\geq 3\%$) with AMRIX were dry mouth, dizziness, fatigue, nausea, dyspepsia, and constipation. Please see brief summary of full prescribing information on the following page.

Reference: 1. Data on file. Studies 1105 and 1106. Cephalon, Inc.; 2004.

Cephalon
deliver more.

©2008 Cephalon, Inc. All rights reserved. AMR139 May 2008 Printed in USA.
AMRIX is produced with Eurand Diffucaps® technology.

For more information about AMRIX, call Cephalon Medical Services at

1-800-896-5855 or visit www.AMRIX.com